All In Biotech

Drug Trial Radar · NCT05144243

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

A Phase 4 Study of Venetoclax in Combination With Azacitidine in Newly Diagnosed Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy in China

Last checked: Nov 20, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

44

Actual

Start

Jan 6, 2022

Primary completion

Mar 2026

Study completion Mar 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
Genentech, Inc.
First posted
Dec 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care. This study is to evaluate how safe the combination of azacitidine and venetoclax is and how effective the combination of azacitidine and venetoclax is in adult participants with acute myeloid leukemia (AML), in China. Adverse events and change in disease state will be assessed. The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing doses of venetoclax. Adult participants with a diagnosis of AML will be enrolled. Around 40 participants will be enrolled in the study in approximately 30 sites in China. At cycle 1 during ramp-up period, participants will receive venetoclax oral tablets once daily in increasing doses until the study dose is achieved on day 3. Then ventoclax oral tablets will continue once daily thereafter. Azacitidine will be given by subcutaneous injection (SC) for 7 days beginning on Day 1 of each 28-day cycle. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • VenetoclaxDrug

    Tablet: Oral

  • AzacitidineDrug

    Subcutaneous Injection (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to Approximately 19 Months
  2. Number of Laboratory Abnormalities from Clinical Laboratory Values (Hematology and Chemistry)Time frame: Up to Approximately 19 Months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Duplicate_The Affiliated Hospital of Guizhou Medical University /ID# 232465

    Guiyang, China

  • Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 233179

    Beijing, Beijing Municipality, China

  • Peking University International Hospital /ID# 232254

    Beijing, Beijing Municipality, China

  • Sun Yat-Sen University Cancer Center /ID# 231793

    Guangzhou, Guangdong, China

  • Zhujiang Hospital of Southern Medical University /ID# 231792

    Guangzhou, Guangdong, China

  • Guangdong Second Provincial General Hospital /ID# 232059

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University /ID# 231938

    Guangzhou, Guangdong, China

  • Shenzhen Second People's Hospital /ID# 231444

    Shenzhen, Guangdong, China

  • People's Hospital of Henan Province /ID# 232568

    Zhengzhou, Henan, China

  • Henan Cancer Hospital /ID# 231940

    Zhengzhou, Henan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 233178

    Wuhan, Hubei, China

  • Xiangyang Central Hospital /ID# 232452

    Xiangyang, Hubei, China

  • The First Affiliated Hospital of Soochow University /ID# 232418

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University /ID# 231442

    Nanchang, Jiangxi, China

  • Qinghai University Affiliated Hospital /ID# 232419

    Xining, Qinghai, China

  • The Second People's Hospital of Yibin /ID# 233180

    Yibin, Sichuan, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 232253

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Wenzhou Medical University /ID# 233704

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.